KemPharm (NASDAQ:KMPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Thursday. The firm presently has a $7.25 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 15.54% from the stock’s previous close.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Other research analysts have also issued research reports about the company. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Friday, March 9th. Oppenheimer reaffirmed a “buy” rating on shares of KemPharm in a research report on Thursday, March 22nd. Royal Bank of Canada set a $9.00 price target on KemPharm and gave the company a “buy” rating in a research report on Tuesday, January 16th. Roth Capital set a $10.00 price target on KemPharm and gave the company a “buy” rating in a research report on Monday, April 2nd. Finally, Canaccord Genuity set a $11.00 price target on KemPharm and gave the company a “buy” rating in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $10.05.
KemPharm (NASDAQ:KMPH) last released its quarterly earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.04). equities research analysts forecast that KemPharm will post -2.59 EPS for the current fiscal year.
A hedge fund recently raised its stake in KemPharm stock. Alyeska Investment Group L.P. grew its position in shares of KemPharm (NASDAQ:KMPH) by 1.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 992,338 shares of the specialty pharmaceutical company’s stock after acquiring an additional 17,721 shares during the period. Alyeska Investment Group L.P. owned about 6.77% of KemPharm worth $3,672,000 at the end of the most recent quarter. Institutional investors own 36.56% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3338156/kempharm-kmph-upgraded-to-buy-by-zacks-investment-research-2.html.
KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.